Stock Scorer

Celldex Therapeutics, Inc. (CLDX)

28.25USD -4.01% (-1.18)

Over 5Y: -47.1%

Style
Area Line Line with markersshows 1Y Steps Candlesshows 6M Hollow candlesshows 6M Barsshows 6M

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

20 40
2022 2023 2024 2025 2026

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›

Celldex Therapeutics, Inc. reported revenue of 22K USD for the quarter ending 30 June 2026, down 97.0% from 730K a year earlier. Every figure, period by period ›

Q3 '21 — Revenue: 153K Q3 '21 — Operating Cash Flow: -16.4M Q3 '21 — Free Cash Flow: -16.6M Q3 '21 — Net Income: -20.5M Q4 '21 — Revenue: 334K Q4 '21 — Operating Cash Flow: -14.5M Q4 '21 — Free Cash Flow: -14.9M Q4 '21 — Net Income: -20.1M Q1 '22 — Revenue: 174K Q1 '22 — Operating Cash Flow: -24.5M Q1 '22 — Free Cash Flow: -25.1M Q1 '22 — Net Income: -23.1M Q2 '22 — Revenue: 163K Q2 '22 — Operating Cash Flow: -22.2M Q2 '22 — Free Cash Flow: -22.9M Q2 '22 — Net Income: -36M Q3 '22 — Revenue: 407K Q3 '22 — Operating Cash Flow: -35.2M Q3 '22 — Free Cash Flow: -35.5M Q3 '22 — Net Income: -26.8M Q4 '22 — Revenue: 1.6M Q4 '22 — Operating Cash Flow: -21.8M Q4 '22 — Free Cash Flow: -22M Q4 '22 — Net Income: -26.5M Q1 '23 — Revenue: 967K Q1 '23 — Operating Cash Flow: -28.6M Q1 '23 — Free Cash Flow: -29.2M Q1 '23 — Net Income: -29.4M Q2 '23 — Revenue: 268K Q2 '23 — Operating Cash Flow: -27.2M Q2 '23 — Free Cash Flow: -27.6M Q2 '23 — Net Income: -30.5M Q3 '23 — Revenue: 1.5M Q3 '23 — Operating Cash Flow: -19M Q3 '23 — Free Cash Flow: -19.1M Q3 '23 — Net Income: -38.3M Q4 '23 — Revenue: 4.1M Q4 '23 — Operating Cash Flow: -32.5M Q4 '23 — Free Cash Flow: -33.2M Q4 '23 — Net Income: -43.3M Q1 '24 — Revenue: 156K Q1 '24 — Operating Cash Flow: -40.6M Q1 '24 — Free Cash Flow: -41M Q1 '24 — Net Income: -32.8M Q2 '24 — Revenue: 2.5M Q2 '24 — Operating Cash Flow: -29.3M Q2 '24 — Free Cash Flow: -29.6M Q2 '24 — Net Income: -35.8M Q3 '24 — Revenue: 3.2M Q3 '24 — Operating Cash Flow: -55.3M Q3 '24 — Free Cash Flow: -55.9M Q3 '24 — Net Income: -42.1M Q4 '24 — Revenue: 1.2M Q4 '24 — Operating Cash Flow: -32.5M Q4 '24 — Free Cash Flow: -33.2M Q4 '24 — Net Income: -47.1M Q1 '25 — Revenue: 695K Q1 '25 — Operating Cash Flow: -54.4M Q1 '25 — Free Cash Flow: -54.6M Q1 '25 — Net Income: -53.8M Q2 '25 — Revenue: 730K Q2 '25 — Operating Cash Flow: -44M Q2 '25 — Free Cash Flow: -44.7M Q2 '25 — Net Income: -56.6M Q3 '25 — Revenue: 0 Q3 '25 — Operating Cash Flow: -48.6M Q3 '25 — Free Cash Flow: -49.1M Q3 '25 — Net Income: -67M Q4 '25 — Revenue: 121K Q4 '25 — Operating Cash Flow: -63.9M Q4 '25 — Free Cash Flow: -65.2M Q4 '25 — Net Income: -81.3M Q1 '26 — Revenue: 15K Q1 '26 — Operating Cash Flow: -65.6M Q1 '26 — Free Cash Flow: -67.2M Q1 '26 — Net Income: -78.7M Q2 '26 — Revenue: 22K Q2 '26 — Operating Cash Flow: -57.4M Q2 '26 — Free Cash Flow: -60.6M Q2 '26 — Net Income: -73.5M -80M -60M -40M -20M 0 20M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

2.3
Accruals -8.3%
Asset turnover 0.0002×
ROA -38.4%
ROCE -45.2%
ROE -42.1%
SG&A / sales 29860.1%

6 of 19 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

2.8
P/C 3.1×
P/B 3.1×
EV/Sales 9499.2×
FCF yield -10.9%
EV/OE -5.4×

5 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.8

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.9
Current ratio 11.8×
Debt / Eq 0.0×
Debt payback 0.0 yr
ND/EBITDA 0.48
Quick ratio 11.8×
Cash runway 3.0 yr
F-score 1.1 pts

11 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.0
Sales CAGR 4Y -24.1%
Sales Q/Q -97.0%
Sales/sh Y/Y -97.4%

6 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.

Companies of a similar size

The nearest by market value among the companies read here whose shares are quoted in USD. Size alone: nothing here says they are in the same business.

Every listed company from the United States, largest first ›